After the discovery of the androgen receptor in 1968, this receptor was also a tempting target for drug developers.37 However, the first antiandrogen, cyproterone, proved to be unsuccessful since it crossed the blood-brain barrier and blocked the androgen receptors of the brain (leading to increased secretion of LH) in addition to blocking the receptors in the testicles.4 This issue was overcome by adding an acetate group to the molecule, thus creating cyproterone acetate, which was approved by the Food and Drug Administration (FDA) for the treatment of PC in 1989.4 Here, AR is linked to pachyonychia congenita.